Hanglok Secures NMPA Class III Medical Device Registration Certificate
2026-03-06 14:00

Hanglok has been granted the Class III Medical Device Registration Certificate (the highest regulatory classification for medical devices in China) by the National Medical Products Administration (NMPA), with registration number:Guo Xie Zhu Zhun 20253012369.


Multi-Modal · Real-Time · Integrated Fusion

Multi-Modal Real-Time Puncture Surgical Robot


·Single-Shot Accurate Puncture for Maximized Procedural Safety

·Real-Time Multi-Dimensional Visualization Through the Entire Procedure

·Millimeter-Level Precision Surpassing the Limits of Human Vision and Manual Operation


Numerous Honors Witness a New Future for Interventional Surgical Robots

· Gold Medal, 11th Guangdong Provincial "Governor's Cup" Industrial Design Competition, 2022
· First Prize, Large Model Healthcare Project Competition, Digital Medical Technology and Application Innovation Conference (DiMTAIC 2024)
· "Potential Unicorn Enterprise", Guangdong-Macao In-Depth Cooperation Zone in Hengqin, December 2024
· "Listed Reserve Enterprise", Recognized by Guangdong-Macao In-Depth Cooperation Zone in Hengqin, March 2025
· First Prize in Life & Health Industry Track & First Prize in Grand Final, 4th "Six Dynasties PineCup" Global Alumni Innovation and Entrepreneurship Competition of Southeast University, June 2025
· Gold Medal in National Final, Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition, September 2025



About Hanglok

Founded in 2020 in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Zhuhai Hanglok Technology Co., Ltd. is a high-tech medical device enterprise specializing in interventional surgical robotics. The company has built a comprehensive portfolio of surgical robot product lines covering percutaneous puncture intervention, natural orifice intervention, and transvascular intervention.

With this landmark regulatory approval, Hanglok is poised to scale its innovative robotic solutions across clinical settings nationwide. The company remains committed to delivering comprehensive, integrated intelligent diagnosis and treatment solutions, and ushering interventional medicine into a new era of unprecedented precision and efficiency.